TRACON Pharmaceuticals, Inc. Common Stock
TCON
TCON was delisted on the 27th of June, 2024.
27 hedge funds and large institutions have $10.9M invested in TRACON Pharmaceuticals, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 14 closing their positions.
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
27% less funds holding
Funds holding: 37 → 27 (-10)
68% less capital invested
Capital invested by funds: $34.4M → $10.9M (-$23.4M)
71% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TI
Telemetry Investments
New York
|
+$795K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$382K |
| 3 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$340K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$51K |
| 5 |
Renaissance Technologies
New York
|
+$44.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$293K |
| 2 |
JP Morgan Chase
New York
|
-$212K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$205K |
| 4 |
Millennium Management
New York
|
-$152K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$125K |
TCON Hedge Fund Activity: Q4 2018 in Review
27 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in TRACON Pharmaceuticals, Inc. Common Stock (TCON) for Q4 2018, worth a combined $10.9M — down 68% from $34.4M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of TCON and 4 opened new positions — a net loss of 10 holders — while 3 trimmed existing stakes and 8 added.
The largest buyer was Telemetry Investments, adding an estimated $795K. The largest seller was Candriam SCA, exiting entirely with an estimated $293K sold.
- 27 institutional investors held TRACON Pharmaceuticals, Inc. Common Stock (TCON) as of Q4 2018, down from 37 in Q3 2018.
- Funds reported $10.9M of TRACON Pharmaceuticals, Inc. Common Stock stock for Q4 2018, down 68% quarter-over-quarter.
- 4 funds opened new TRACON Pharmaceuticals, Inc. Common Stock positions in Q4 2018 and 14 closed out, a net change of -10 holders.
- The largest TRACON Pharmaceuticals, Inc. Common Stock buyer in Q4 2018 was Telemetry Investments, an estimated $795K added.
- The largest TRACON Pharmaceuticals, Inc. Common Stock seller in Q4 2018 was Candriam SCA, an estimated $293K sold.
Based on aggregated 13F filings for Q4 2018.